



(12)

Oversættelse af europæisk patentskrift

Patent- og
Varemærkestyrelsen

(51) Int.Cl.: **A 61 K 31/706 (2006.01)** **A 61 K 31/245 (2006.01)** **A 61 K 31/4184 (2006.01)**
A 61 K 31/7068 (2006.01) **A 61 K 31/708 (2006.01)** **A 61 K 45/06 (2006.01)**
A 61 P 35/00 (2006.01)

(45) Oversættelsen bekendtgjort den: **2020-03-30**

(80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2020-01-08**

(86) Europæisk ansøgning nr.: **13851971.5**

(86) Europæisk indleveringsdag: **2013-10-30**

(87) Den europæiske ansøgnings publiceringsdag: **2015-09-09**

(86) International ansøgning nr.: **US2013067607**

(87) Internationalt publikationsnr.: **WO2014070948**

(30) Prioritet: **2012-10-30 US 201261720346 P**

(84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(73) Patenthaver: **MEI Pharma, Inc., 11975 El Camino Real, Suite 101, San Diego, CA 92130, USA**

(72) Opfinder: **GOLD, Daniel, P., 11975 El Camino Real, Suite 101, San Diego, CA 92130, USA**
GARCIA-MANERO, Guillermo, c/o University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 428, Houston, TX 77030, USA

(74) Fuldmægtig i Danmark: **Pure Ideas Ltd, 25 Meer Street, Stratford-upon-Avon, Warwickshire, CV37 6QB, Storbritannien**

(54) Benævnelse: **COMBINATION THERAPIES TO TREAT CHEMORESISTANT CANCERS**

(56) Fremdragne publikationer:
US-A1- 2009 048 300
US-A1- 2010 098 691
ELLIOT J MITMAKER ET AL: "Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors", SURGERY, MOSBY, INC, US, vol. 149, no. 4, 18 October 2010 (2010-10-18), pages 504-511, XP028163759, ISSN: 0039-6060, DOI: 10.1016/J.SURG.2010.10.007 [retrieved on 2010-10-22]
JOANNA EDYTA FRACZEK ET AL: "Synergistic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 30, no. 4, 29 March 2011 (2011-03-29) , pages 1715-1724, XP035079569, ISSN: 1573-0646, DOI: 10.1007/S10637-011-9659-8

DK/EP 2914254 T3

DESCRIPTION

BACKGROUND OF THE INVENTION

[0001] Local chromatin architecture is generally recognized as an important factor in the regulation of gene expression. The architecture of chromatin, a protein-DNA complex, is strongly influenced by post-translational modifications of the histones which are the protein components. Reversible acetylation of histones is a key component in the regulation of gene expression by altering the accessibility of transcription factors to DNA. In general, increased levels of histone acetylation are associated with increased transcriptional activity, whereas decreased levels of acetylation are associated with repression of gene expression [Wadom P.A. *Hum. Mol. Genet.* 10, 693-698 (2001), De Ruijter A.J.M. et al, *Biochem. J.*, 370, 737-749 (2003)]. In normal cells, histone deacetylases (HDACs) and histone acetyltransferase together control the level of acetylation of histones to maintain a balance. Inhibition of HDACs results in the accumulation of acetylated histones, which results in a variety of cell type dependent cellular responses, such as apoptosis, necrosis, differentiation, cell survival, inhibition of proliferation and cytostasis.


[0002] Inhibitors of HDAC have been studied for their therapeutic effects on cancer cells. For example, suberoylanilide hydroxamic acid (SAHA) is a potent inducer of differentiation and/or apoptosis in murine erythroleukemia, bladder, and myeloma cell lines [Richon V.M. et al, *Proc. Natl. Acad. Sci. USA*, 93: 5705-5708 (1996), Richon V.M. et al, *Proc. Natl. Acad. Sci. USA*, 95: 3003-3007 (1998)]. SAHA has been shown to suppress the growth of prostate cancer cells *in vitro* and *in vivo* [Butler L.M. et al, *Cancer Res.* 60, 5165-5170 (2000)]. Other inhibitors of HDAC that have been widely studied for their anti-cancer activities are trichostatin A (TSA) and trapoxin B [Yoshida M. et al, *J. Biol. Chem.*, 265, 17174 (1990), Kijima M. et al, *J. Biol. Chem.*, 268, 22429 (1993)]. Trichostatin A is a reversible inhibitor of mammalian HDAC. Trapoxin B is a cyclic tetrapeptide, which is an irreversible inhibitor of mammalian HDAC. However, due to the *in vivo* instability of these compounds they are less desirable as anti-cancer drugs. Recently, other small molecule HDAC inhibitors have become available for clinical evaluation [US 6,552,065]. Additional HDAC inhibiting compounds have been reported in the literature [Bouchain G. et al, *J. Med. Chem.*, 46, 820-830 (2003)] and patents [WO 03/066579A2]. The *in vivo* activity of such inhibitors can be directly monitored by their ability to increase the amount of acetylated histones in the biological sample. HDAC inhibitors have been reported to interfere with neurodegenerative processes, for instance, HDAC inhibitors arrest polyglutamine-dependent neurodegeneration [*Nature*, 413(6857): 739-43, 18 October, 2001]. In addition, HDAC inhibitors have also been known to inhibit production of cytokines such as TNF, IFN, IL-1 which are known to be implicated in inflammatory diseases and/or immune system disorders. [*J. Biol. Chem.* 1990; 265(18): 10232-10237; *Science*, 1998; 281: 1001-1005; Dinarello C.A. and Moldawer L.L. *Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis, A primer for clinicians*, 3rd Edition, Amgen Inc., 2002].

[0003] US 2010/09869 discloses compounds which may be used to treat myelodysplastic syndrome. Mitmaker E. J. et al., *Surgery*, 2010; 149(4): 504-511, discloses the use of demethylating agents and histone deacetylase inhibitors in treating thyroid cancer.

[0004] Nevertheless, there is still a need to provide further HDAC inhibitor combinations that would be expected to have useful, improved pharmaceutical properties in the treatment of diseases such as cancer, neurodegenerative diseases, disorders involving angiogenesis and inflammatory and/or immune system disorders.


SUMMARY OF THE INVENTION

[0005] The present invention provides a DNA hypomethylating agent and a compound of formula (Id):



wherein

R¹ is a group having the formula:



R² is alkyl, fluoroalkyl, cyano, C₂-C₆alkenyl, C₂-C₆alkynyl, or heteroalkyl optionally substituted with =O;


each R²⁰, R²¹, R²², R²³, R²⁴, and R²⁵ is independently H or methyl;

each R²⁶ and R²⁷ is independently H, hydroxylalkyl, or alkyl; and


m, n, and o are independently integers of 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt for use in treating chemoresistant cancer selected from myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

[0006] In some embodiments, the compound of formula (Id) has the structure of formula (Ie) or (If):



R^{26} R^{27}
Formula (Ie)



Formula (If)

wherein


R^2 is alkyl, fluoroalkyl, cyano, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, or heteroalkyl optionally substituted with $=O$;

each R^{20} , R^{21} , R^{22} , R^{23} , R^{24} , and R^{25} is independently H or methyl; and

each R^{26} and R^{27} is independently H, hydroxylalkyl, or alkyl;


or a pharmaceutically acceptable salt.

[0007] Described herein in some embodiments is a compound of formulas (Id), (Ie), or (If) wherein R^{26} and R^{27} are independently H or alkyl. In specific embodiments, R^{26} and R^{27} are independently H, methyl, ethyl, isopropyl, propyl, butyl, isobutyl, pentyl, hexyl or heptyl. In some embodiments, R^1 has the structure:



[0008] In some embodiments, R^2 is ethyl, 1-methyl-ethyl, 2,2,2-trifluoroethyl, propyl, 2-methyl-propyl, 2,2-dimethyl-propyl, 3,3,3-trifluoro-propyl, butyl, 3,3-dimethyl-butyl, pentyl, 2,4,4-trimethyl-pentyl, hexyl or octyl. In some specific embodiments, R^2 is butyl.

[0009] In some embodiments, the compound of formula (Id) is 3-[2-Butyl-1-(2-diethylaminoethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide. In some embodiments, the compound of formula (Id) has the structure:




[0010] Also described are cases wherein the DNA hypomethylating agent is 5-azacytidine (azacitidine), 5-azadeoxycytidine (decitabine), SGI-110, zebularine or procaine. In certain specific embodiments, the DNA hypomethylating agent is 5-azacytidine (azacitidine).


[0011] Also described are cases wherein the disease or disorder associated with dysregulation of histone deacetylase is cancer. Also described are cases wherein the cancer is a hematological malignancy such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, thrombolytic leukemia, a myelodysplastic syndrome (MDS), a myeloproliferative disorder, refractory anemia, a preleukemia syndrome, a lymphoid leukemia, lymphoma, non-Hodgkin's lymphoma, or an undifferentiated leukemia. In some specific embodiments, the cancer is myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Also described are cases wherein the non-Hodgkin's lymphoma is diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL). In some embodiments, the cancer is refractory, non-responsive or resistant to chemotherapy and/or haploidentical stem cell transplantation. In some embodiments, the cancer is resistant to azacitidine, decitabine, SGI-110, lenalidomide, TXA-127, or combinations thereof. In some embodiments, the cancer is resistant to azacitidine, decitabine, lenalidomide, TXA-127, or combinations thereof.

[0012] In some embodiments, a compound of formula (Id), (Ie) or (If) is administered in an amount from 5 mg to 120 mg, for example about 60 mg. In some embodiments, the DNA hypomethylating agent is administered in an amount from 5 mg/m² to 125 mg/m². In other embodiments, the DNA hypomethylating agent is administered in an amount of 75 mg/m². In some embodiments, the compound for use in the invention is administered orally and the DNA hypomethylating agent is administered intravenously or subcutaneously. In some embodiments, the DNA hypomethylating agent is administered intravenously. Described herein in certain embodiments is the use of a compound of formula (Id) as herein before defined or a pharmaceutically acceptable salt thereof for use together with a hypomethylating agent for treating chemoresistant cancer.

[0013] In some embodiments, the cancer is a hematological malignancy. In some embodiments, the cancer is myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). In certain embodiments, the cancer is resistant to azacitidine, decitabine, SGI-110, lenalidomide, TXA-127, or combinations thereof. In some embodiments, the cancer is resistant to azacitidine, decitabine, lenalidomide, TXA-127, or combinations thereof.

[0014] In some embodiments, the compound of formula (Id) is 3-[2-Butyl-1-(2-diethylaminoethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide. In some embodiments, the compound of formula (Id) has the structure:






[0015] In some embodiments, the DNA hypomethylating agent is 5-azacytidine (azacitidine).

[0016] Also described herein are kits comprising one or more containers filled with a DNA hypomethylating agent and one or more containers filled with a compound of formula (Id) as defined herein before.


[0017] In some embodiments, the compound has the structure of formula (Id):



Formula (Id)

wherein

R¹ is a group having the formula:



R² is alkyl, fluoroalkyl, cyano, C₂-C₆alkenyl, C₂-C₆alkynyl, or heteroalkyl optionally substituted with =O;


each R²⁰, R²¹, R²², R²³, R²⁴, and R²⁵ is independently H or methyl;

each R²⁶ and R²⁷ is independently H, hydroxylalkyl, or alkyl; and

m, n, and o are independently integers of 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt.

[0018] In some embodiments, the kit comprises 5-azacytidine (azacitidine) as the DNA hypomethylating agent and the compound of formula (Id) having the structure:



DETAILED DESCRIPTION

[0019] There is a continuing need to develop and provide effective therapies for the treatment of disease and disorders associated with dysregulation of histone deacetylase (e.g., cancer). Described herein in some embodiments is a combination therapy for treating cancer.

Certain Definitions

[0020] Unless otherwise noted, terminology used herein should be given its normal meaning as understood by one of skill in the art.

[0021] As used herein, the term unsubstituted means that there is no substituent or that the only substituents are hydrogen.

[0022] The term "optionally substituted" as used throughout the specification denotes that the group may or may not be further substituted with the named substituent group =O. "Alkyl" as a group or part of a group refers to a straight or branched C₁-C₆ aliphatic hydrocarbon group, preferably a C₁-C₃. Examples of suitable straight and branched C₁-C₆ alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl, hexyl, and the like. The group may be a terminal group or a bridging group.

[0023] "Alkenyl" as a group or part of a group denotes an C₂-6 aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched. The group may contain a plurality of double bonds in the normal chain and the orientation about each is independently E or Z. Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl and hexenyl. The group may be a terminal group or a bridging group.

[0024] "Alkynyl" as a group or part of a group means a C₂-6 aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched. Exemplary structures include, but are not limited to, ethynyl and propynyl. The group may be a terminal group or a bridging group.

[0025] "Heteroalkyl" refers to a straight- or branched-chain alkyl group preferably having from 2 to 14 atoms, more preferably 2 to 10 atoms in the chain, one or more of which is a heteroatom selected from S, O, and N. Exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, alkyl sulfides, and the like. The group may be a terminal group or a bridging group.

[0026] It is understood that included in the family of compounds of Formula (Id) are isomeric forms including diastereoisomers, enantiomers, tautomers, and geometrical isomers in "E" or

"Z" configurational isomer or a mixture of E and Z isomers. It is also understood that some isomeric forms such as diastereomers, enantiomers, and geometrical isomers can be separated by physical and/or chemical methods and by those skilled in the art.

[0027] Some of the compounds of the disclosed embodiments may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and for diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the subject matter described and claimed.

[0028] Additionally, Formula (Id) is intended to cover, where applicable, solvated as well as unsolvated forms of the compounds. Thus, each formula includes compounds having the indicated structure, including the hydrated as well as the non-hydrated forms.

[0029] The HDAC inhibiting agents for use in the various embodiments include pharmaceutically acceptable salts of such compounds.


[0030] The term "pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the above-identified compounds, and include pharmaceutically acceptable acid addition salts and base addition salts. Suitable pharmaceutically acceptable acid addition salts of compounds of Formula (Id) may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, sulfuric, and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, fumaric, maleic, alkyl sulfonic, arylsulfonic. Suitable pharmaceutically acceptable base addition salts of compounds of Formula (Id) include metallic salts made from lithium, sodium, potassium, magnesium, calcium, aluminium, and zinc, and organic salts made from organic bases such as choline, diethanolamine, morpholine. Other examples of organic salts are: ammonium salts, quaternary salts such as tetramethylammonium salt; amino acid addition salts such as salts with glycine and arginine. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Co., Easton, PA 1995. In the case of agents that are solids, it is understood by those skilled in the art that the inventive compounds, agents and salts may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulae.

[0031] The term "therapeutically effective amount" or "effective amount" is an amount sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations. An effective amount is typically sufficient to palliate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state. A therapeutically effective amount can be readily determined by an attending diagnostician by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective amount a number of factors are to be considered including but not limited to, the species of animal, its size, age and general health, the specific condition involved, the severity of the condition, the response of the patient to treatment, the particular

compound administered, the mode of administration, the bioavailability of the preparation administered, the dose regime selected, the use of other medications and other relevant circumstances.


HDAC Inhibiting Agents

[0032] The compound for use in the invention has the structure of formula (Id):



wherein

R¹ is a group having the formula:



R² is alkyl, fluoroalkyl, cyano, C₂-C₆alkenyl, C₂-C₆alkynyl, or heteroalkyl optionally substituted with =O;


each R²⁰, R²¹, R²², R²³, R²⁴, and R²⁵ is independently H or methyl;

each R²⁶ and R²⁷ is independently H, hydroxylalkyl, or alkyl; and

m, n, and o are independently integers of 0, 1, 2, 3, or 4;


or a pharmaceutically acceptable salt thereof.

[0033] In some embodiments, the compound of formula (Id) has the structure of formula (Ie) or (If):



Formula (Ic)

wherein



Formula (If)

R² is alkyl, fluoroalkyl, cyano, C₂-C₆alkenyl, C₂-C₆alkynyl, or heteroalkyl optionally substituted


with =O;


each R²⁰, R²¹, R²², R²³, R²⁴, and R²⁵ is independently H or methyl; and

each R²⁶ and R²⁷ is independently H, hydroxylalkyl, or alkyl;

or a pharmaceutically acceptable salt thereof.

[0034] In another embodiment R¹ is a group selected from the group consisting of:







[0035] In one specific embodiment R^1 is a group of formula:




[0036] In another specific embodiment R¹ is a group of formula:



[0037] In another specific embodiment R¹ is a group of formula:




[0038] In yet another specific embodiment R¹ is a group of formula:



[0039] In another specific embodiment R¹ is a group of formula:




[0040] In another specific embodiment R¹ is a group of formula:



[0041] In another specific embodiment R¹ is a group of formula:




[0042] In another specific embodiment R¹ is a group of formula:



[0043] In another specific embodiment R¹ is a group of formula:












[0044] In one case R² is alkyl. In one case the alkyl is a C₁-C₁₀ alkyl. In another form the alkyl is a C₁-C₆ alkyl group. In another form R² is selected from the group consisting of: methyl; ethyl; propyl; 2-methyl-propyl; 2,2-dimethyl-propyl; isopropyl; 3,3,3-trifluoropropyl; butyl; isobutyl; 3,3- dimethyl-butyl; pentyl; 2,4,4-trimethyl-pentyl; hexyl; heptyl, octyl, nonyl, and 2-methoxy nonyl.








[0045] In one form of this embodiment R² is alkenyl. In one form of this embodiment the alkenyl is a C₂-C₁₀ alkenyl. In another form of this embodiment the alkenyl is a C₂-C₆ alkenyl group. In another form of this embodiment R² is selected from the group consisting of: ethenyl, prop-1-enyl, prop-2-enyl, but-1-enyl, but-2-enyl but-3-enyl, pent-1- enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl and hex-5-enyl. Specific values of R² are selected from the group consisting of: methyl; 2,2,2-trifluoro-ethyl; propyl; 2-2-dimethyl-propyl; isopropyl; 3,3,3-trifluoro-propyl; butyl; isobutyl; 3,3-dimethyl-butyl; but-3-enyl; but-3-ynyl; pentyl; 2,4,4-trimethyl-pentyl; hexyl; hex-3-enyl; ,







[0046] Preferred HDAC inhibiting agents include those having an IC₅₀ value of 10 µM or less.


[0047] Specific compounds for use in the invention include the following:

	3-[1-(3-Dimethylamino-2,2-dimethyl-propyl)-2-(2,2-dimethyl-propyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(3-Dimethylamino-2,2-dimethyl-propyl)-2-isopropyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[2-Butyl-1-(3-dimethylamino-2,2-dimethylpropyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(3-Dimethylamino-2,2-dimethyl-propyl)-2-(2-methylsulfanyl-ethyl)-1H-benzimidazol-5-yl]-N-


	hydroxy-acrylamide
	3-[1-(3-Dimethylamino-2,2-dimethyl-propyl)-2-ethoxymethyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(3-Dimethylamino-2,2-dimethyl-propyl)-2-isobutyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Diethylamino-ethyl)-2-isobutyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[2-Butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[2-But-3-ynyl-1-(3-dimethylamino-2,2-dimethyl-propyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[2-But-3-enyl-1-(3-dimethylamino-2,2-dimethyl-propyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[2-But-3-enyl-1-(2-diethylamino-ethyl)-1H-

	benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[2-But-3-ynyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(3-Dimethylamino-2,2-dimethyl-propyl)-2-(3,3,3-trifluoro-propyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Diethylamino-ethyl)-2-(3,3,3-trifluoro-propyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Diethylamino-ethyl)-2-ethoxymethyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(3-Dimethylamino-2,2-dimethyl-propyl)-2-methyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Diethylamino-ethyl)-2-(2,2-dimethyl-propyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide


	<p>N-Hydroxy-3-[1-(3-isopropylamino-propyl)-2-(3,3,3-trifluoro-propyl)-1H-benzimidazol-5-yl]-acrylamide</p>
	<p>3-[2-(2,2-Dimethyl-propyl)-1-(2-isopropylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>3-[1-(2-Diisopropylamino-ethyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>3-[1-(2-Diisopropylamino-ethyl)-2-isobutyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>3-[1-(3-Dimethylamino-2,2-dimethyl-propyl)-2-hex-3-enyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>3-[1-(3-Dimethylamino-2,2-dimethyl-propyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>




3-[1-(2-Diethylamino-ethyl)-2-hex-3-enyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide




3-[1-(2-Diisopropylamino-ethyl)-2-hex-3-enyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide




3-[2-Hex-3-enyl-1-(2-isopropylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide




3-[2-Hex-3-enyl-1-(3-isopropylamino-propyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide










3-[1-(2-Ethylamino-ethyl)-2-hex-3-enyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide

















3-[1-(2-Diethylamino-ethyl)-2-hexyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
















N-Hydroxy-3-[1-(3-isopropylamino-propyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzimidazol-5-yl]-acrylamide








	
	3-[2-(2,2-Dimethyl-propyl)-1-(3-isopropylaminopropyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Diisopropylamino-ethyl)-2-(3,3,3-trifluoropropyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	N-Hydroxy-3-[2-isobutyl-1-(2-isopropylaminoethyl)-1H-benzimidazol-5-yl]-acrylamide
	3-[2-(2,2-Dimethyl-propyl)-1-(2-ethylaminoethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Ethylamino-ethyl)-2-isobutyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1 -(2-Diisopropylamino-ethyl)-2-(2,4,4-trimethylpentyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide





	<p>N-Hydroxy-3-[1-(2-isopropylamino-ethyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzimidazol-5-yl]-acrylamide</p>
	<p>3-[1-(2-Ethylamino-ethyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>3-[1-(2-Diethylamino-ethyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>3-[1-(2-Diethylamino-ethyl)-2-propyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>3-[2-Butyl-1-(2-diisopropylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>3-[1-(2-Diethylamino-ethyl)-2-(2-methylsulfanyl-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>3-[2-Butyl-1-(2-isopropylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>3-[2-Butyl-1-(3-isopropylamino-propyl)-1H-</p>






	benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[2-But-3-enyl-1-(2-ethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[2-Hexyl-1-(2-isopropylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Dimethylamino-ethyl)-2-(2,4,4-trimethylpentyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Ethylamino-ethyl)-2-hexyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	N-Hydroxy-3-[1-(2-isopropylamino-ethyl)-2-(3,3,3-trifluoro-propyl)-1H-benzimidazol-5-yl]-acrylamide
	3-[1-(2-Dimethylamino-ethyl)-2-hex-3-enyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide



	3-[1-(2-Amino-ethyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[2-Butyl-1-(2-dimethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Dimethylamino-ethyl)-2-hexyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-ethylamino-ethyl)-2-(3,3-dimethylbutyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[2-(3,3-Dimethyl-butyl)-1-(2-Dimethylaminoethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Dimethylamino-ethyl)-2-pentyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-(2-Dimethylamino-ethyl)-2-(2,2,2-trifluoroethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide

	<p>N-Hydroxy-3-[1-(5-methyl-1H-pyrazol-3-yl)-2-(2,4,4-trimethyl-pentyl)-1H-benzimidazol-5-yl]-acrylamide</p>
	<p>3-[1-(2-Ethylamino-ethyl)-2-pentyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>N-Hydroxy-3-[1-(2-isopropylamino-ethyl)-2-pentyl-1H-benzimidazol-5-yl]-acrylamide</p>
	<p>3-[2-Hexyl-1-[1-(2-methylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide</p>
	<p>N-Hydroxy-3-[1-(2-methylamino-ethyl)-2-pentyl-1H-benzimidazol-5-yl]-acrylamide</p>
	<p>N-Hydroxy-3-[1-(2-methylamino-ethyl)-2-octyl-1H-benzimidazol-5-yl]-acrylamide</p>
	<p>3-[1-(2-Amino-ethyl)-2-octyl-1H-benzimidazol-</p>

	5-yl]-N-hydroxy-acrylamide
	3-{2-Butyl-1-[2-(isopropyl-methyl-amino)-ethyl]-1H-benzimidazol-5-yl}-N-hydroxy-acrylamide
	3-{1[2-(Ethyl-methyl-amino)-ethyl]-2-pentyl-1H-benzimidazol-5-yl}-N-hydroxy-acrylamide
	3-{2-Butyl-1-[2-(ethyl-methyl-amino)-ethyl]-1H-benzimidazol-5-yl}-N-hydroxy-acrylamide
	3-(2-Butyl-1-{2-ethyl-(3-hydroxy-propyl)-amino}-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-(1-{2-[Ethyl-(3-hydroxy-propyl)-amino]-ethyl}-2-pentyl-1H-benzimidazol-5-yl)-N-hydroxy acrylamide
	3-[1-(2-Diethylamino-ethyl)-2-propylamino-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide

	3-{1-[2-Ethyl-hexyl-amino]-ethyl}-2-methyl-1H-benzimidazol-5-yl-N-hydroxy-acrylamide
	3-{1-[2-(Butyl-ethyl-amino)-ethyl]-2-trifluoromethyl-1H-benzimidazol-5-yl}-N-hydroxy-acrylamide
	3-{1-[2-(Ethyl-hexyl-amino)-ethyl]-2-trifluoromethyl-1H-benzimidazol-5-yl}-N-hydroxy-acrylamide
	(E)-3-(1-(2-(dibutylamino)ethyl)-2-propyl-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide

	3-[1-(2-Dipropylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	N-Hydroxy-3-(1-{2-[isopropyl-(3-methyl-butyl)-amino]-ethyl}-1H-benzimidazol-5-yl)-acrylamide
	3-(1-{2-[(3,3-Dimethyl-butyl)-methyl-amino]-ethyl}-1H-benzimidazol-5-yl)-N-hydroxy-acrylamide
	3-[1-[2-(3,3-Dimethyl-butylamino)-ethyl]-2-propyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-[2-(3,3-Dimethyl-butylamino)-ethyl]-2-(2,2-dimethyl-propyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-[1-{2-[Bis-(3,3-dimethyl-butyl)-amino]-

	3-[1-{2-(2-(3,3-Dimethyl-butylamino)-ethyl)-2-ethyl-1H-benzimidazol-5-yl}-2-ethyl-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide
	3-(1-{2-[(3,3-Dimethyl-butyl)-methylaminoethyl]-2-propyl-1H-benzimidazol-5-yl}-2-ethyl-1H-benzimidazol-5-yl)-N-hydroxy-acrylamide

[0048] The compounds of formula (Id) and the embodiments disclosed herein inhibit histone deacetylases. In certain embodiments, the histone deacetylase inhibitor interacts with and/or reduces the activity of more than one known histone deacetylase in the cell, which can either be from the same class of histone deacetylase or different class of histone deacetylase. In some other embodiments, the histone deacetylase inhibitor interacts and reduces the activity of predominantly one histone deacetylase, for example HDAC-1, HDAC-2, HDAC-3 or HDAC-8 which belongs to Class I HDAC enzymes [De Ruijter A.J.M. et al, Biochem. J., 370, 737-749 (2003)]. In some embodiments, the compounds of formula (Id) have significant anti-proliferative effects and promote differentiation, cell cycle arrest in the G1 or G2 phase, and induce apoptosis.

DNA Hypomethylating Agents

[0049] Any suitable hypomethylating agent may be used in combination with a compound of formula (Id). DNA hypomethylating agents for use in the methods provided herein include but

are not limited to 5-azacytidine (azacitidine), 5-azadeoxycytidine (decitabine), SGI-110, zebularine and procaine. In certain specific embodiments, the DNA hypomethylating agent is 5-azacytidine (azacitidine).

Methods

[0050] Described herein are methods of treating a disease or disorder associated with dysregulation of histone deacetylase, comprising administering to a subject in need thereof an effective amount of (i) a DNA hypomethylating agent, and (ii) a compound of formula (Id). In some embodiments, the DNA hypomethylating agent acts additively with a compound of formula (Id). In some cases, the DNA hypomethylating agent acts synergistically with a compound of formula (Id). In some cases, a compound of formula (Id) is a compound of formula (Ie), or (If).

[0051] Some cases described are methods of treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis including administration of a therapeutically effective amount of a DNA hypomethylating agent and a compound of formula (Id). In some embodiments, a compound of formula (Id) is a compound of formula (Ie) or (If).

[0052] Also described herein are agents for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis. In some embodiments, the agents are a DNA hypomethylating agent and a compound of formula (Id), (Ie) or (If).

[0053] Some cases described herein relate to the use of a DNA hypomethylating agent and a compound of formula (Id) in the preparation of a medicament for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis. In one case, the disorder is a proliferative disorder. In a specific embodiment, the disorder is a cancer. In some cases, the combination therapy of a DNA hypomethylating agent and a compound of formula (Id) show low toxicity. In some embodiments, the combination therapy of a DNA hypomethylating agent and a compound of formula (Id) show potent anti-proliferative activity.

[0054] Other cases described herein provide a method of treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase including administration of a therapeutically effective amount of a DNA hypomethylating agent and a compound of formula (Id). In some embodiments, a compound of formula (Id) is a compound of formula (Ie) or (If).

[0055] Also described herein are agents for use in the treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase. In one embodiment the agent is an anticancer agent. In some embodiments, the agents are a DNA hypomethylating agent and a compound of formula (Id). In some embodiments, a compound of formula (Id) is a

compound of formula, (Ie) or (If).

[0056] Some cases described herein provide a method for inhibiting cell proliferation including administration of an effective amount of a DNA hypomethylating agent and a compound according to formula (Id).

[0057] Described herein in certain cases is a method of treating chemoresistant cancer comprising administering to a subject in need thereof an effective amount of a DNA hypomethylating agent and a compound of formula (Id). In some embodiments, the cancer is refractory, non-responsive or resistant to chemotherapy. In some embodiments, the cancer is refractory, non-responsive or resistant to haploidentical stem cell transplantation. In some embodiments, the cancer is resistant to azacitidine, decitabine, SGI-110, lenalidomide, TXA-127, or combinations thereof. In some embodiments, the cancer is resistant to azacitidine, decitabine, lenalidomide, TXA-127, or combinations thereof.

[0058] In one case the disorder is selected from the group consisting of but not limited to cancer (e.g. breast cancer, colon cancer, prostate cancer, pancreatic cancer, leukemia, lymphomas, ovarian cancers, neuroblastomas, melanoma). In another case the disorder is a proliferative disorder. In one embodiment the proliferative disorder is cancer. The cancer can include solid tumors or hematologic malignancies.

[0059] In some cases, the methods described herein are useful in treating various cancers including but not limited to bone cancers including Ewing's sarcoma, osteosarcoma, chondrosarcoma and the like, brain and CNS tumours including acoustic neuroma, neuroblastomas, glioma and other brain tumours, spinal cord tumours, breast cancers including ductal adenocarcinoma, metastatic ductal breast carcinoma, colorectal cancers, advanced colorectal adenocarcinomas, colon cancers, endocrine cancers including adenocortical carcinoma, pancreatic cancer, pituitary cancer, thyroid cancer, parathyroid cancer, thymus cancer, multiple endocrine neoplasia, gastrointestinal cancers including stomach cancer, esophageal cancer, small intestine cancer, liver cancer, extra hepatic bile duct cancer, gastrointestinal carcinoid tumour, gall bladder cancer, genitourinary cancers including testicular cancer, penile cancer, prostate cancer, gynaecological cancers including cervical cancer, ovarian cancer, vaginal cancer, uterus/endometrium cancer, vulva cancer, gestational trophoblastic cancer, fallopian tube cancer, uterine sarcoma, head and neck cancers including oral cavity cancer, lip cancer, salivary gland cancer, larynx cancer, hypopharynx cancer, orthopharynx cancer, nasal cancer, paranasal cancer, nasopharynx cancer, leukemias including childhood leukemia, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, acute promyelocytic leukemia, plasma cell leukemia, erythroleukemia, myelomas, haematological disorders including myelodysplastic syndromes, myeloproliferative disorders, aplastic anemia, Fanconi anemia, Waldenstroms Macroglobulinemia, lung cancers including small cell lung cancer, non-small cell lung cancer, mesothelioma, lymphomas including Hodgkin's disease, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, AIDS related Lymphoma, B-cell lymphoma, Burkitt's lymphoma, eye cancers including retinoblastoma, intraocular

melanoma, skin cancers including melanoma, non-melanoma skin cancer, squamous cell carcinoma, merkel cell cancer, soft tissue sarcomas such as childhood soft tissue sarcoma, adult soft tissue sarcoma, Kaposi's sarcoma, urinary system cancers including kidney cancer, Wilms tumour, bladder cancer, urethral cancer, and transitional cell cancer.

[0060] In some cases, the disease or disorder associated with dysregulation of histone deacetylase is cancer. In some cases, the cancer is a hematological malignancy. In some embodiments, wherein the hematological malignancy is acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, thrombolytic leukemia, a myelodysplastic syndrome (MDS), a myeloproliferative disorder, refractory anemia, a preleukemia syndrome, a lymphoid leukemia, lymphoma, non-Hodgkin's lymphoma, or an undifferentiated leukemia. In some specific cases, the cancer is myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Non-limiting examples of non-Hodgkin's lymphoma include diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL).

[0061] Other exemplary cancers that may be treated by the methods described herein include but are not limited to leukemias such as erythroleukemia, acute promyelocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, acute T-cell leukemia and lymphoma such as B-cell lymphoma (e.g. Burkitt's lymphoma), cutaneous T-cell lymphoma (CTCL), and peripheral T-cell lymphoma.

[0062] Certain exemplary cancers that may be treated by the methods described herein include solid tumors and hematologic malignancies. In another case, preferred cancers that may be treated with the compounds of the present invention are colon cancer, prostate cancer, hepatoma and ovarian cancer.

Doses

[0063] The amount of a DNA hypomethylating agent and a compound of formula (Id) will be dependent on the subject treated. In some instances where the subject is a human, the dose will normally be determined by the prescribing physician with the dosage generally varying according to the age, sex, diet, weight, general health and response of the individual patient, the severity of the patient's symptoms, the precise indication or condition being treated, the severity of the indication or condition being treated, time of administration, route of administration, the disposition of the composition, rate of excretion, and the discretion of the prescribing physician. In some embodiments, the total dosage for the day is divided and administered in portions during the day if desired. In some embodiments, combinational applications in which the combination therapy described herein is not the sole therapy, allows for the administration of lesser amounts of a DNA hypomethylating agent and a compound of formula (Id).

[0064] In some embodiments, the dosage of a compound of formula (Id) ranges from about

0.01 to 300 mg per kilogram of body weight per day. In other embodiments, the dosage of a compound of formula (Id) ranges from 0.1 to 100 mg per kilogram of body weight per day, from 0.2 to 80 mg per kilogram of body weight per day, and from 0.2 to 50 mg per kilogram of body weight per day.

[0065] In specific embodiments, an effective amount of a compound of formula (Id) is from about 5 mg to about 1000 mg, from about 5 mg to about 120 mg, from about 10 mg to about 1000 mg, from about 10 mg to about 900 mg, from about 10 mg to about 800 mg, from about 10 mg to about 700 mg, from about 10 mg to about 600 mg, from about 10 mg to about 500 mg, from about 10 mg to about 400 mg, from about 10 mg to about 300 mg, from about 10 mg to about 250 mg, from about 10 mg to about 200 mg, from about 10 mg to about 150 mg, from about 10 mg to about 125 mg, from about 10 mg to about 120 mg, from about 10 mg to about 100 mg, from about 10 mg to about 90 mg, from about 10 mg to about 80 mg, from about 10 mg to about 70 mg, from about 10 mg to about 60 mg, from about 10 mg to about 50 mg, from about 10 mg to about 40 mg, from about 10 mg to about 30 mg, from about 30 mg to about 1000 mg, from about 30 mg to about 500 mg, from about 30 mg to about 400 mg, from about 30 mg to about 300 mg, from about 30 mg to about 200 mg, from about 30 mg to about 250 mg, from about 30 mg to about 225 mg, from about 30 mg to about 200 mg, from about 30 mg to about 175 mg, from about 30 mg to about 150 mg, from about 30 mg to about 125 mg, from about 30 mg to about 120 mg, from about 30 mg to about 115 mg, from about 30 mg to about 110 mg, from about 30 mg to about 100 mg, from about 30 mg to about 90 mg, from about 30 mg to about 80 mg, from about 30 mg to about 70 mg, from about 30 mg to about 60 mg, from about 30 mg to about 50 mg, from about 40 mg to about 100 mg, from about 40 mg to about 80 mg, from about 50 mg to about 70 mg, from about 60 mg to about 500 mg, from about 60 mg to about 250 mg, from about 60 mg to about 200 mg, from about 60 mg to about 150 mg, from about 30 mg to about 125 mg, from about 30 mg to about 120 mg, from about 100 mg to about 500 mg, from about 100 mg to about 400 mg, from about 100 mg to about 300 mg, from about 100 mg to about 200 mg, less than 1000 mg, less than 900 mg, less than 800 mg, less than 700 mg, less than 600 mg, less than 500 mg, less than 400 mg, less than 300 mg, less than 275 mg, less than 250 mg, less than 225 mg, less than 200 mg, less than 175 mg, less than 150 mg, less than 125 mg, less than 100 mg, less than 90 mg, less than 80 mg, less than 70 mg, less than 65 mg, less than 60 mg, less than 55 mg, less than 50 mg, less than 40 mg, less than 30 mg, less than 20 mg, less than 10 mg, about 1000 mg, about 950 mg, about 900 mg, about 850 mg, about 800 mg, about 750 mg, about 700 mg, about 650 mg, about 600 mg, about 550 mg, about 500 mg, about 450 mg, about 400 mg, about 350 mg, about 300 mg, about 250 mg, about 200 mg, about 190 mg, about 180 mg, about 170 mg, about 160 mg, about 150 mg, about 140 mg, about 130 mg, about 120 mg, about 110 mg, about 100 mg, about 95 mg, about 90 mg, about 85 mg, about 80 mg, about 75 mg, about 70 mg, about 65 mg, about 60 mg, about 55 mg, about 50 mg, about 45 mg, about 40 mg, about 35 mg, about 30 mg, about 25 mg, about 20 mg, about 15 mg, about 10 mg, about 8 mg, about 5 mg, about 2 mg, or about 1 mg. In certain specific embodiment, an effective amount of a compound of formula (Id) administered according to any of the methods described herein is about 60 mg.

[0066] In specific cases, an effective amount of DNA hypomethylating agent is from about 5

mg/m² to about 1000 mg/m², from about 5 mg/m² to about 125 mg/m², from about 10 mg/m² to about 1000 mg/m², from about 10 mg/m² to about 800 mg/m², from about 10 mg/m² to about 700 mg/m², from about 10 mg/m² to about 600 mg/m², from about 10 mg/m² to about 500 mg/m², from about 10 mg/m² to about 400 mg/m², from about 10 mg/m² to about 350 mg/m², from about 10 mg/m² to about 300 mg/m², from about 10 mg/m² to about 200 mg/m², from about 10 mg/m² to about 175 mg/m², from about 10 mg/m² to about 150 mg/m², from about 10 mg/m² to about 125 mg/m², from about 10 mg/m² to about 115 mg/m², from about 10 mg/m² to about 100 mg/m², from about 10 mg/m² to about 80 mg/m², from about 10 mg/m² to about 60 mg/m², from about 10 mg/m² to about 20 mg/m², from about 5 mg/m² to about 20 mg/m², from about 50 mg/m² to about 500 mg/m², from about 50 mg/m² to about 400 mg/m², from about 10 mg/m² to about 350 mg/m², from about 50 mg/m² to about 300 mg/m², from about 50 mg/m² to about 250 mg/m², from about 50 mg/m² to about 225 mg/m², from about 50 mg/m² to about 200 mg/m², from about 50 mg/m² to about 175 mg/m², from about 50 mg/m² to about 150 mg/m², from about 50 mg/m² to about 125 mg/m², from about 50 mg/m² to about 100 mg/m², from about 50 mg/m² to about 80 mg/m², from about 60 mg/m² to about 80 mg/m², from about 75 mg/m² to about 250 mg/m², from about 75 mg/m² to about 200 mg/m², from about 75 mg/m² to about 150 mg/m², from about 75 mg/m² to about 125 mg/m², less than 1000 mg/m², less than 900 mg/m², less than 800 mg/m², less than 700 mg/m², less than 600 mg/m², less than 500 mg/m², less than 400 mg/m², less than 350 mg/m², less than 300 mg/m², less than 275 mg/m², less than 250 mg/m², less than 225 mg/m², less than 200 mg/m², less than 175 mg/m², less than 150 mg/m², less than 125 mg/m², less than 115 mg/m², less than 100 mg/m², less than 90 mg/m², less than 80 mg/m², less than 70 mg/m², less than 60 mg/m², less than 50 mg/m², less than 40 mg/m², less than 30 mg/m², less than 20 mg/m², less than 10 mg/m², about 1000 mg/m², about 900 mg/m², about 800 mg/m², about 700 mg/m², about 600 mg/m², about 500 mg/m², about 400 mg/m², about 350 mg/m², about 300 mg/m², about 250 mg/m², about 225 mg/m², about 200 mg/m², about 175 mg/m², about 150 mg/m², about 140 mg/m², about 130 mg/m², about 125 mg/m², about 115 mg/m², about 100 mg/m², about 90 mg/m², about 95 mg/m², about 90 mg/m², about 85 mg/m², about 80 mg/m², about 75 mg/m², about 70 mg/m², about 65 mg/m², about 60 mg/m², about 50 mg/m², about 55 mg/m², about 45 mg/m², about 40 mg/m², about 35 mg/m², about 30 mg/m², about 25 mg/m², about 20 mg/m², about 15 mg/m², about 11 mg/m², about 10 mg/m², about 5 mg/m², or about 2 mg/m². In certain specific cases, an effective amount of a DNA hypomethylating agent administered according to any of the methods described herein is about 75 mg/m².

Administration

[0067] In some cases, a compound of formula (Id) and a DNA hypomethylating agent are administered to a subject (e.g., a human) by any acceptable modes for enteral administration such as oral or rectal, or by parenteral administration such as subcutaneous, intramuscular, intravenous and intradermal routes. In some cases injection is bolus or via constant or intermittent infusion. In various cases, the combination of a compound of formula (Id) and a DNA hypomethylating agent is selectively toxic or more toxic to rapidly proliferating cells, e.g. cancerous tumors, than to normal cells.

[0068] The compounds for use in the present invention can be administered alone or in the form of a pharmaceutical composition in combination with a pharmaceutically acceptable carrier, diluent or excipient. The compounds for use in the invention, while effective themselves, are typically formulated and administered in the form of their pharmaceutically acceptable salts as these forms are typically more stable, more easily crystallised and have increased solubility.

[0069] In some cases, a compound of formula (Id) and a DNA hypomethylating agent are used in the form of pharmaceutical compositions which are formulated depending on the desired mode of administration. In some cases, a pharmaceutical composition includes a compound of formula (Id) and a pharmaceutically acceptable carrier, diluent or excipient. In other cases, a pharmaceutical composition includes a DNA hypomethylating agent and a pharmaceutically acceptable carrier, diluent or excipient. In certain cases, a pharmaceutical composition includes a compound of formula (Id), a DNA hypomethylating agent, and at least one pharmaceutically acceptable carrier, diluents or excipient. In certain specific cases, the compound of formula (Id) is 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide. In certain specific cases, the DNA hypomethylating agent is 5-azacitidine. In certain specific cases, the DNA hypomethylating agent is 5-azadeoxycytidine.

[0070] Some cases provided herein describe pharmaceutical compositions for parenteral injection comprising pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Non-limiting examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. In some embodiments, proper fluidity is maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0071] In some cases, provided herein are compositions containing adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. In some cases, various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like are included to prevent the action of microorganisms. In some cases, the

pharmaceutical composition includes isotonic agents such as sugars, sodium chloride, and the like. In some cases, prolonged absorption of the injectable pharmaceutical form is brought about by the inclusion of agents that delay absorption such as aluminium monostearate and gelatin.

[0072] In some cases, for more effective distribution, the active agents are incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.

[0073] In certain cases, the injectable formulations is sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that are dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

[0074] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0075] In some cases, solid compositions comprise fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[0076] In some instances, the solid dosage forms of tablets, dragees, capsules, pills, and granules are prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. In some cases, the solid dosage forms optionally contain opacifying agents and release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

[0077] In some cases, the compounds are incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.

[0078] In some cases, the active compounds are in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0079] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In some instances, the liquid dosage forms contains inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

[0080] In some instances, the oral compositions also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0081] In some cases, any compound of formula (Id) is administered intravenously, subcutaneously, or orally. In certain embodiments, a compound of formula (Id) is administered orally. In certain specific cases, 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide is administered orally. In certain specific embodiments, 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide is administered intravenously.

[0082] In some cases, a DNA hypomethylating agent is administered intravenously, subcutaneously, or orally. In certain cases, a DNA hypomethylating agent is administered intravenously. In other cases, a DNA hypomethylating agent is administered subcutaneously. In certain specific cases, 5-azacitidine is administered intravenously. In other specific cases, 5-azacitidine is administered subcutaneously. In certain specific cases, 5-azadeoxycytidine is administered intravenously. In other specific cases, 5-azadeoxycytidine is administered subcutaneously.

[0083] Also described herein is a combination therapy comprising a compound of formula (Id) and a DNA hypomethylating agent, wherein the compound of formula (Id) and the DNA hypomethylating agent are administered in combination with each other. In some instances, the compound of formula (Id) and the DNA hypomethylating agent are administered simultaneously. In other instances, the compound of formula (Id) and the DNA hypomethylating agent are administered sequentially. In other instances, the compound of formula (Id) and the DNA hypomethylating agent are administered within the same week.

[0084] In some cases, the compound of formula (Id) is administered daily, every other day, every other day 3 times a week, every 3 days, every 4 days, every 5 days, every 6 days, weekly, bi-weekly, 3 times a week, 4 times a week, 5 times a week, 6 times a week, once a month, twice a month, 3 times a month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, or once every 6 months. In some cases, the DNA hypomethylating agent is administered daily, every other day, every other day 3 times a week, every 3 days, every 4 days, every 5 days, every 6 days, weekly, bi-weekly, 3 times a week, 4 times a week, 5 times a week, 6 times a week, once a month, twice a month, 3 times a month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, or

once every 6 months.

[0085] In some instances, the compound of formula (Id) or the DNA hypomethylating agent is optionally given continuously; alternatively, the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a "drug holiday"). The length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

[0086] Also described herein is a combination therapy that is used or administered in combination with one or more additional drug (s) that are chemotherapeutic drugs or HDAC inhibitor drugs and/or procedures (e.g. surgery, radiotherapy) for the treatment of the disorder/diseases mentioned. In some embodiments, the additional drug(s) are administered in the same formulation or in separate formulations. In some embodiments, if administered in separate formulations, the combination therapy is administered sequentially or simultaneously (as a combined preparation) with the additional drug(s).

Kits

[0087] Describe herein is a pharmaceutical pack or kit comprising one or more containers filled with a compound of formula (Id) and one or more containers filled with a DNA hypomethylating agent. In some cases, the kit comprises one container filled with a compound of formula (Id) and a DNA hypomethylating agent. In some cases, the kit comprises a container having a unit dosage of the agent(s). In certain cases, the kits include one or more compositions comprising a compound of formula (Id) and a DNA hypomethylating agent (including lyophilized compositions), which can be diluted further prior to use or they can be provided at the concentration of use, where the vials may include one or more dosages. Conveniently, in the kits, single dosages can be provided in sterile vials so that the physician can employ the vials directly, where the vials will have the desired amount and concentration of agent(s). Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

[0088] In some cases, the kit comprises a container filled with 3-[2-butyl-1-(2-diethylaminoethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide and 5-azacitidine. In other cases, the kit comprises a container filled with 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide and 5-azadeoxycytidine. In some cases, the kit comprises one or more containers filled with 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-

benzimidazol-5-yl]-N-hydroxy-acrylamide and one or more containers filled with 5-azacitidine. In other cases, the kit comprises one or more containers filled with 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide and one or more containers filled with 5-azadeoxycytidine.

EXAMPLES

Example 1. Treatment of Hematological Malignancies

Human Clinical Trial of the Safety and Efficacy of Combination Therapy for Hematological Malignancies

[0089] Study Design: This pilot phase II study was conducted as an extension study in the context of a phase I trial of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide in hematological malignancies to determine the efficacy and safety of the combination of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide (60 mg orally every other day 3 times a week for 3 consecutive weeks) and 5-azacitidine (75 mg/m² IV daily x 5 every 3 to 6 weeks) given in 4-week cycles to patients with intermediate-2 or high risk MDS.

[0090] Nine patients (6 women) were accrued between May 2011 and September 2011. The median age of the patients was 64 years (range, 22-73), WBC 2.4x10⁹/dL (0.7-9.3), Hg 10g/dL (8.2-11), platelets 31x10⁹/dL (14-269), and bone marrow blasts 7% (0%-18%). Seven (78%) patients had therapy-related myelodysplastic syndrome (MDS) with a history of prior chemotherapy/radiotherapy exposure (3 breast cancer, 2 non-Hodgkin's lymphoma, 1 breast and ovarian cancer, and 1 melanoma). Three patients had failed prior therapy: decitabine and haploidentical stem cell transplantation (SCT; n=1), lenalidomide (n=1), and decitabine and TXA-127 (n=1). All patients carried cytogenetic abnormalities: complex (n=4, 3 including -7 and 1 with -5), -7 (n=3, one of them with +8), t(6;9) (n=1), and t(14;16) and del(20) (n=1). Two patients with -7 also carried gene mutations: 1 in CEBPa and 1 IDH2^{R140Q}. Patients received a median of 4 cycles.

[0091] Results: All 9 patients were evaluable. The overall response rate (ORR; defined as rate of complete response (CR) + CR with incomplete platelet recovery (Cri) + rate of partial response (PR)) is 8/9 (89%) and the CR + Cri rate is 7/9 (78%). Five (56%) patients achieved a complete cytogenetic response, including the patient carrying IDH2R140Q, in whom such mutation became undetectable. Eight-week mortality was 0%. Only 1 (11%) patient died, unrelated to study drug (after allogeneic-SCT). The median duration of response was 45 days (0-229). Reasons for discontinuation were: transition to allogeneic-SCT (n=5), no availability of

3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide by sponsor (n=2), no response (n=1), and progression to AML (n=1). The combination was well tolerated. All toxicities were grade 1 or 2. The most frequent toxicities were fatigue and nausea (56% each).

[0092] The combination of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide and 5-azacitidine was very well tolerated in patients with MDS. The preliminary ORR of 89% is very encouraging, considering that most patients in this study had high-risk cytogenetics and/or had treatment related MDS, both subsets of MDS with very poor prognosis.

Example 2. Combination Treatment for Acute Myeloid Leukemia

Human Clinical Trial of the Safety and Efficacy of 3-[2-Butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide and 5-Azacitidine for Treatment of Acute Myeloid Leukemia (AML)

[0093] Study Design: This study will be a Phase II study in acute myeloid leukemia patients. Patients must not have received treatment for their cancer within 2 weeks of beginning the trial. Treatments include the use of chemotherapy, hematopoietic growth factors, and biologic therapy such as monoclonal antibodies. Patients must have recovered from all toxicities (to grade 0 or 1) associated with previous treatment. All subjects are evaluated for safety and all blood collections for pharmacokinetic analysis are collected as scheduled. All studies are performed with institutional ethics committee approval and patient consent.

[0094] Phase II: Patients receive 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide (orally every other day 3 times a week for 4 consecutive weeks) and 5-azacitidine (intravenously daily x 5 every 4 weeks). Treatment repeats every 4 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.

[0095] Blood Sampling Serial blood is drawn by direct vein puncture before and after administration of compound 31. Venous blood samples (5 mL) for determination of serum concentrations are obtained at about 10 minutes prior to dosing and at approximately the following times after dosing: days 1, 8, 15, and 22. Each serum sample is divided into two aliquots. All serum samples are stored at -20°C. Serum samples are shipped on dry ice.

[0096] Pharmacokinetics: Patients undergo plasma/serum sample collection for

pharmacokinetic evaluation before beginning treatment and at days 1, 8, 15, and 22. Pharmacokinetic parameters are calculated by model independent methods on a Digital Equipment Corporation VAX 8600 computer system using the latest version of the BIOAVL software. The following pharmacokinetics parameters are determined: peak serum concentration (C_{max}); time to peak serum concentration (t_{max}); area under the concentration-time curve (AUC) from time zero to the last blood sampling time (AUC_{0-72}) calculated with the use of the linear trapezoidal rule; and terminal elimination half-life ($t_{1/2}$), computed from the elimination rate constant. The elimination rate constant is estimated by linear regression of consecutive data points in the terminal linear region of the log-linear concentration-time plot. The mean, standard deviation (SD), and coefficient of variation (CV) of the pharmacokinetic parameters are calculated for each treatment. The ratio of the parameter means (preserved formulation/non-preserved formulation) is calculated.

[0097] Patient Response to combination therapy: Patient response is assessed via imaging with X-ray, CT scans, MRI, and imaging is performed prior to beginning the study and at the end of the first cycle, with additional imaging performed every four weeks or at the end of subsequent cycles. Imaging modalities are chosen based upon the cancer type and feasibility/availability, and the same imaging modality is utilized for similar cancer types as well as throughout each patient's study course. Response rates are determined using the RECIST criteria. (Therasse et al, J. Natl. Cancer Inst. 2000 Feb 2; 92(3):205-16; <http://ctep.cancer.gov/forms/TherasseRECISTJNCI.pdf>). Patients also undergo cancer/tumor biopsy to assess changes in progenitor cancer cell phenotype and clonogenic growth by flow cytometry, Western blotting, and IHC, and for changes in cytogenetics by FISH. After completion of study treatment, patients are followed periodically for 4 weeks.

[0098] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Example 3. Combination Treatment for Acute Myeloid Leukemia

Human Clinical Trial of the Safety and Efficacy of 3-[2-Butyl-1-(2-diethylaminoethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide and 5-azadeoxycytidine for Treatment of Acute Myeloid Leukemia (AML)

[0099] Study Design: This study will be a Phase II study in acute myeloid leukemia patients.

Patients must not have received treatment for their cancer within 2 weeks of beginning the trial. Treatments include the use of chemotherapy, hematopoietic growth factors, and biologic therapy such as monoclonal antibodies. Patients must have recovered from all toxicities (to grade 0 or 1) associated with previous treatment. All subjects are evaluated for safety and all blood collections for pharmacokinetic analysis are collected as scheduled. All studies are performed with institutional ethics committee approval and patient consent.

[0100] Phase II: Patients receive 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide (orally every other day 3 times a week for 4 consecutive weeks) and 5-azadeoxycytidine (intravenously daily x 5 every 4 weeks). Treatment repeats every 4 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.

[0101] Blood Sampling Serial blood is drawn by direct vein puncture before and after administration of compound 31. Venous blood samples (5 mL) for determination of serum concentrations are obtained at about 10 minutes prior to dosing and at approximately the following times after dosing: days 1, 8, 15, and 22. Each serum sample is divided into two aliquots. All serum samples are stored at -20°C. Serum samples are shipped on dry ice.

[0102] Pharmacokinetics: Patients undergo plasma/serum sample collection for pharmacokinetic evaluation before beginning treatment and at days 1, 8, 15, and 22. Pharmacokinetic parameters are calculated by model independent methods on a Digital Equipment Corporation VAX 8600 computer system using the latest version of the BIOAVL software. The following pharmacokinetics parameters are determined: peak serum concentration (C_{max}); time to peak serum concentration (t_{max}); area under the concentration-time curve (AUC) from time zero to the last blood sampling time (AUC_{0-72}) calculated with the use of the linear trapezoidal rule; and terminal elimination half-life ($t_{1/2}$), computed from the elimination rate constant. The elimination rate constant is estimated by linear regression of consecutive data points in the terminal linear region of the log-linear concentration-time plot. The mean, standard deviation (SD), and coefficient of variation (CV) of the pharmacokinetic parameters are calculated for each treatment. The ratio of the parameter means (preserved formulation/non-preserved formulation) is calculated.

[0103] Patient Response to combination therapy: Patient response is assessed via imaging with X-ray, CT scans, MRI, and imaging is performed prior to beginning the study and at the end of the first cycle, with additional imaging performed every four weeks or at the end of subsequent cycles. Imaging modalities are chosen based upon the cancer type and feasibility/availability, and the same imaging modality is utilized for similar cancer types as well as throughout each patient's study course. Response rates are determined using the RECIST criteria. (Therasse et al, J. Natl. Cancer Inst. 2000 Feb 2; 92(3):205-16; <http://ctep.cancer.gov/forms/TherasseRECISTJNCI.pdf>). Patients also undergo cancer/tumor

biopsy to assess changes in progenitor cancer cell phenotype and clonogenic growth by flow cytometry, Western blotting, and IHC, and for changes in cytogenetics by FISH. After completion of study treatment, patients are followed periodically for 4 weeks.

[0104] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Example 4. Combination Treatment for Myelodysplastic Syndrome (MDS)

Human Clinical Trial of the Safety and Efficacy of 3-[2-Butyl-1-(2-diethylaminoethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide and 5-azadeoxycytidine for Treatment of myelodysplastic syndrome (MDS)

[0105] Study Design: This study will be a Phase II study in myelodysplastic syndrome patients. Patients must not have received treatment for their cancer within 2 weeks of beginning the trial. Treatments include the use of chemotherapy, hematopoietic growth factors, and biologic therapy such as monoclonal antibodies. Patients must have recovered from all toxicities (to grade 0 or 1) associated with previous treatment. All subjects are evaluated for safety and all blood collections for pharmacokinetic analysis are collected as scheduled. All studies are performed with institutional ethics committee approval and patient consent.

[0106] Phase II: Patients receive 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzimidazol-5-yl]-N-hydroxy-acrylamide (orally every other day 3 times a week for 4 consecutive weeks) and 5-azadeoxycytidine (intravenously daily x 5 every 4 weeks). Treatment repeats every 4 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.

[0107] Blood Sampling Serial blood is drawn by direct vein puncture before and after administration of compound 31. Venous blood samples (5 mL) for determination of serum concentrations are obtained at about 10 minutes prior to dosing and at approximately the following times after dosing: days 1, 8, 15, and 22. Each serum sample is divided into two aliquots. All serum samples are stored at -20°C. Serum samples are shipped on dry ice.

[0108] Pharmacokinetics: Patients undergo plasma/serum sample collection for pharmacokinetic evaluation before beginning treatment and at days 1, 8, 15, and 22. Pharmacokinetic parameters are calculated by model independent methods on a Digital Equipment Corporation VAX 8600 computer system using the latest version of the BIOAVL software. The following pharmacokinetics parameters are determined: peak serum concentration (C_{max}); time to peak serum concentration (t_{max}); area under the concentration-time curve (AUC) from time zero to the last blood sampling time (AUC_{0-72}) calculated with the use of the linear trapezoidal rule; and terminal elimination half-life ($t_{1/2}$), computed from the elimination rate constant. The elimination rate constant is estimated by linear regression of consecutive data points in the terminal linear region of the log-linear concentration-time plot. The mean, standard deviation (SD), and coefficient of variation (CV) of the pharmacokinetic parameters are calculated for each treatment. The ratio of the parameter means (preserved formulation/non-preserved formulation) is calculated.

[0109] Patient Response to combination therapy: Patient response is assessed via imaging with X-ray, CT scans, MRI, and imaging is performed prior to beginning the study and at the end of the first cycle, with additional imaging performed every four weeks or at the end of subsequent cycles. Imaging modalities are chosen based upon the cancer type and feasibility/availability, and the same imaging modality is utilized for similar cancer types as well as throughout each patient's study course. Response rates are determined using the RECIST criteria. (Therasse et al, J. Natl. Cancer Inst. 2000 Feb 2; 92(3):205-16; <http://ctep.cancer.gov/forms/TherasseRECISTJNCI.pdf>). Patients also undergo cancer/tumor biopsy to assess changes in progenitor cancer cell phenotype and clonogenic growth by flow cytometry, Western blotting, and IHC, and for changes in cytogenetics by FISH. After completion of study treatment, patients are followed periodically for 4 weeks.

[0110] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims be covered thereby.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description


- [US6552065B \[0002\]](#)
- [WO03066579A2 \[0002\]](#)
- [US201009869B \[0003\]](#)

Non-patent literature cited in the description

- **WADEM P.A.** *Hum. Mol. Genet.*, 2001, vol. 10, 693-698 [\[0001\]](#)
- **DE RUIJTER A.J.M. et al.** *Biochem. J.*, 2003, vol. 370, 737-749 [\[0001\]](#) [\[0048\]](#)
- **RICHON V.M. et al.** *Proc. Natl. Acad. Sci. USA*, 1996, vol. 93, 5705-5708 [\[0002\]](#)
- **RICHON V.M. et al.** *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 3003-3007 [\[0002\]](#)
- **BUTLER L.M. et al.** *Cancer Res.*, 2000, vol. 60, 5165-5170 [\[0002\]](#)
- **YOSHIDA M. et al.** *J. Biol. Chem.*, 1990, vol. 265, 17174- [\[0002\]](#)
- **KIJIMA M. et al.** *J. Biol. Chem.*, 1993, vol. 268, 22429- [\[0002\]](#)
- **BOUCHAIN G. et al.** *J. Med. Chem.*, 2003, vol. 46, 820-830 [\[0002\]](#)
- *Nature*, 2001, vol. 413, 6857739-43 [\[0002\]](#)
- *J. Biol. Chem.*, 1990, vol. 265, 1810232-10237 [\[0002\]](#)
- *Science*, 1998, vol. 281, 1001-1005 [\[0002\]](#)
- Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis **DINARELLO C.A.** **MOLDAWER L.L.** A primer for clinicians Amgen Inc. 20020000 [\[0002\]](#)
- **MITMAKER E. J. et al.** *Surgery*, 2010, vol. 149, 4504-511 [\[0003\]](#)
- Remington's Pharmaceutical Sciences Mack Publishing Co. 19950000 [\[0030\]](#)
- **THERASSE et al.** *J. Natl. Cancer Inst.*, 2000, vol. 92, 3205-16 [\[0097\]](#)
- **THERASSE et al.** *J. Natl. Cancer Inst.*, 2000, vol. 92, 3205-16 [\[0103\]](#) [\[0109\]](#)

Kombinationsterapier til behandling af kemoresistente cancere**PATENTKRAV**

1. DNA-hypomethyleringsmiddel og forbindelse med formlen (Id):



Formel (Id)

hvor

R¹ er en gruppe med formlen:

-(CR²⁰R²¹)_m-(CR²²R²³)_n-(CR²⁴R²⁵)_o-NR²⁶R²⁷;

R² er alkyl, fluoralkyl, cyano, C₂-C₆-alkenyl, C₂-C₆-alkynyl eller heteroalkyl eventuelt substitueret med =O;

hver R²⁰, R²¹, R²², R²³, R²⁴ og R²⁵ uafhængigt er H eller methyl;

hver R²⁶ og R²⁷ uafhængigt er H, hydroxylalkyl eller alkyl; og

m, n og o uafhængigt er heltal på 0, 1, 2, 3 eller 4;

eller et farmaceutisk acceptabelt salt;


til anvendelse i behandling af kemoresistent cancer udvalgt fra myelodysplastisk syndrom (MDS) eller akut myeloid leukæmi (AML).

2. DNA-hypomethyleringsmiddel og forbindelse til anvendelse ifølge krav 1, hvor R²⁶ og R²⁷ uafhængigt er H eller alkyl.

3. DNA-hypomethyleringsmiddel og forbindelse til anvendelse ifølge krav 2 hvor R²⁶ og R²⁷ uafhængigt er H, methyl, ethoyl, isopropyl, propyl, butyl, isobutyl, hexyl og heptyl.

4. DNA-hypomethyleringsmiddel og forbindelse til anvendelse ifølge krav 1 til 3, hvor R¹ er CH₂CH₂N(CH₂CH₃)₂.

5. DNA-hypomethyleringsmiddel og forbindelse til anvendelse ifølge krav 1 eller 2, hvor R² er butyl.
6. DNA-hypomethyleringsmiddel og forbindelse til anvendelse ifølge et af kravene 1 eller 5, hvor canceren er resistent over for azacitidin, decitabin, lenalidomid, TXA-127 eller kombinationer deraf.
7. DNA-hypomethyleringsmiddel og forbindelse til anvendelse ifølge et hvilket som helst af kravene 1-6, hvor forbindelsen med formlen (Id) har strukturen:



8. DNA-hypomethyleringsmiddel og forbindelse til anvendelse ifølge et hvilket som helst af kravene 1-7, hvor DNA-hypomethyleringsmidlet er 5-azacytidin (azacitidin).
9. DNA-hypomethyleringsmiddel og forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor DNA-hypomethyleringsmidlet er 5-azacytidin (azacitidin), 5-azadeoxycytidin (decitabin), SGI-110, zebularin eller procain.